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Background: Animal sport such as horseracing is tainted with drug abuse as are human sports. Treatment of
racehorses on race day with therapeutic medications in most cases is banned, and thus, it is essential to monitor
the illicit use of drugs in the racing horse to maintain integrity of racing, ensure fair competition and protect the
health, safety and welfare of the horse, jockeys and drivers. In the event of a dispute over the identity of the sample
donor, if the regulator can provide evidence that the DNA genotype profile of the post-race sample matched that
of the alleged donor, then the potential drug violation case might be easily resolved without legal challenges.
Case description: We present a case study of a racehorse sample that tested positive for dexamethasone in a post-race
plasma sample in Pennsylvania (PA) but the result was challenged by the trainer of the horse. Dexamethasone is a
synthetic glucocorticoid widely used in the management of musculoskeletal problems in horses but its presence in the
horse during competition is banned by the PA Racing Commissions. The presence of dexamethasone in the
post-competition plasma sample was confirmed using liquid chromatography-tandem mass spectrometry. However, this
finding was challenged by the trainer of the horse alleging that the post-race sample was not collected from his/her
horse and thus petitioned the Commission to be absolved of any wrong-doing. To resolve the dispute, a DNA test was
ordered by the PA Racing Commission to identify the correct donor of the dexamethasone positive sample. For
this purpose, a 24-plex short tandem repeat analysis to detect 21 equine markers and three human markers
was employed. The results indicated that all the samples tested had identical DNA profiles and thus, it was
concluded that the samples were collected from the same horse and that the probability of drawing a false
conclusion was approximately zero (1.5 × 10-15).
Conclusions: The plasma sample confirmed for the presence of dexamethasone was collected from the alleged
horse.
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Animal sport such as horseracing is tainted with drug
abuse as are human sports. Corticosteroids are steroidal
anti-inflammatory drugs frequently used in racehorses to
manage inflammation due to injury. It may mask pain to
the extent that it would allow the horse to compete earlier
than it is supposed to. The potential of a breakdown on
the track by a horse that is prematurely racing is particu-
larly dangerous because it puts the safety, health and wel-
fare of the horse and lives of all other participants in the
race at a great risk. To alleviate this potential problem, a
rapid through-put screening, quantification and confirm-
ation method was developed and put in place for the de-
tection and confirmation of corticosteroids in post-race
equine plasma samples (Luo et al., 2005). Treatment with
therapeutic medications by the attending veterinarian to
take care of a sick horse is allowed but it is against the
regulation for a horse to compete while there is a quantifi-
able and confirmable concentration of any corticosteroid
in the horse during competition.
In the event of a dispute over the identity of the sample
donor, if the regulator can provide evidence of the DNA
genotype profile of the post-race sample matching that of
the alleged animal donor and of no other source of DNA
present in the sample, then the potential drug violation
case might be easily resolved without costly legal chal-
lenges. In response to the need for matching of a con-
tested sample to the correct donor in the racing industry,
we developed a novel 24-plex short tandem repeats (STR)
analysis to detect 21 equine STR markers and three hu-
man markers to check for sample contamination by hu-
man DNA (Chen et al., 2010a).
This study presents a case of a post-race plasma sam-
ple that tested positive for the presence of dexametha-
sone but the result was challenged by the trainer of the
horse claiming that the sample was not collected from
his/her horse. When DNA profiles of the post-race sam-
ples (urine and plasma) and those of the alleged horse
samples were compared using the novel 24-plex STR
genotyping system, there was an indisputable match in
the DNA profiles indicating that the post-race samples
matched those of the alleged horse.
Case description
All post-race samples were collected and witnessed by the
respective trainer or representative. Sampling was ap-
proved by the Institutional Animal Care and Use Commit-
tee of the University of Pennsylvania. The samples were
sealed according to the procedures that satisfy unbroken
chain of custody as required by our Standard Operating
Procedures and the accreditation Guidelines under ISO/
IEC 17025. The samples were stored under proper condi-
tions (urine and plasma at −20°C, whole blood and strands
of hair at 4°C). Fifteen days after the post-race sampletested positive for dexamethasone, blood and strands of
hair were collected from the alleged Standardbred horse
by the attending veterinarian. Collection of the samples
was witnessed by a PA Racing Commission representative
and the horse trainer.
Routine drug screening analyses were performed on the
post-race samples as previously described (You et al., 2009).
The presence of dexamethasone in a post-race plasma sam-
ple was detected, quantified and confirmed using liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
(Luo et al., 2005). Briefly, dexamethasone was recovered
from plasma by liquid-liquid extraction using methyl tert-
butyl ether. Analyte was separated on a Hypercarb column
(2.1 × 30 mm) with acetonitrile:water:formic acid (95:5:0.5,
v/v/v) mixture as the mobile phase and analyzed by positive
electrospray ionization mode with selected reaction moni-
toring (SRM) on a triple quadrupole mass spectrometer
(Finnigan TSQ Quantum Ultra with Accela Autosampler,
Thermo Fisher Scientific, San Jose, CA, USA) (You et al.,
2009). Retention time (tR) for dexamethasone was 1.08 ±
0.10 min. For screening and quantification analysis, SRM of
m/z 393→ 355 transition was employed. Three ion transi-
tions (m/z 393→ 355, m/z 393→ 337 and m/z 393→ 319)
were monitored for confirmation. Similarity in ion intensity
ratio and tR were used as confirmation criteria. Deuterium-
labeled dexamethasone (d4-dexamethasone, C/D/N ISO-
TOPES Inc., Quebec, Canada) was used as the internal
standard (IS) for quantification. The linear calibration
range was 0.25 - 100 ng/mL (r2 > 0.999). Limits of detec-
tion and quantification were 0.1 ng/mL and 0.25 ng/mL,
respectively.
Dexamethasone was detected, quantified (2.12 ±
0.14 ng/mL) and confirmed in one of the post-race plasma
samples (Figure 1). Limits of detection, quantification and
confirmation were 0.10, 0.25 and 0.50 ng/mL, respectively.
Betamethasone is an isomer of dexamethasone and under
normal analysis using liquid chromatography and mass
spectrometry, dexamethasone cannot be distinguished from
betamethasone because of similarity in chemical structure
resulting in similarity in tR, mass spectrum and product
ion spectrum. However, both compounds were chromato-
graphically separated (Figure 1) (Luo et al., 2005). Based
on this study, tR of betamethasone was distinctly different
from that of dexamethasone on the Hypercarb column and
thus, these two drugs were chromatographically resolved
(Figure 1E) from one another. In addition, the presence of
dexamethasone in the post-race test sample was confirmed
by chromatographic peak ion intensity ratio comparison
and tR (Figure 2).
Genomic DNA was isolated from blood, plasma, urine
and hair root of the alleged horse using Genorise DNA
Isolation Kits (Chen et al., 2010a) and quantified using
agarose gel and OD260 using TotalLab software (Chen
et al., 2009). Genomic DNA was also prepared from blood
RT: 0.00 - 4.01 SM: 5B
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Figure 1 LC-ESI(+)-MS/SRM chromatograms of dexamethasone in a post-race plasma, dexamethasone as calibrator and betamethasone
as an isomer of dexamethasone. Top three panels represent blank plasma (A), blank plasma + IS (B) and solvent blank (C), all of which were
scanned for the presence of dexamethasone only at m/z 393→ 355. Panel D is dexamethasone detected in the post-race plasma sample
collected from the alleged horse while panel E shows chromatographic resolution of dexamethasone (left) from betamethasone (right) spiked in
blank plasma, extracted and analyzed. The tR (1.05 min) of post-race plasma containing dexamethasone was similar to that for dexamethasone
spiked plasma (calibrator) and the difference was within ± 0.1 min.
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as well as human hair for positive and negative control
samples. A total of 2950 ng of DNA was recovered from
0.3 mL test plasma sample, 25 ng of DNA from 1 mL test
urine, after the samples were refrigerated for 30 days. A
total of 14.4 μg of DNA was obtained from 0.3 mL alleged
blood sample while 56 ng of DNA was recovered from a
single hair root; both of which were refrigerated for 24 h
prior to DNA extraction.
Polymerase chain reaction (PCR) was conducted to
detect STR as previously described (Chen et al., 2010a).
Briefly, PCR primer pairs were designed to amplify twenty-
one equine dinucleotide and three human tetranucleotide
repeat markers for simultaneous detection of the STR
markers in the suspect horse as well as in the control sam-
ples. One of each paired primers was labeled with one of
three cyanine-based fluorescent dyes (WellRED D2-PA,
D3-PA, and D4-PA; Beckman Coulter) to distinguishbetween markers. Twenty-one equine and three human
STR markers were co-amplified in a reaction of 15 μL in a
single tube in a thermocycler using Qiagen HotStar DNA
Polymerase Master Kit.
To acquire the STR profile of the alleged horse and of
the control samples, fragment analysis of amplified STR
products was performed (Chen et al., 2010a). Briefly, fol-
lowing initial verification of amplified STR fragments using
1.2% agarose gel, the visualized PCR products were further
analyzed using capillary electrophoresis to determine the
size of each STR marker. An aliquot (1 μL) of PCR prod-
ucts was analyzed on a CEQ8800 Genetic Analysis System
(Beckman Coulter, Brea, CA, USA) and the size of each
marker was estimated by automatic comparison with an
internal size standard-600 using Fragment Analysis soft-
ware. An allele was designated as the number of repeat
unit plus 0.1 for partial repeat (one nucleotide) (Budowle
et al., 2005). A complete DNA profile was obtained from
RT: 0.00 - 1.60 SM: 5B
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Figure 2 Analyte confirmation by ion intensity ratio comparison of dexamethasone in a post-race plasma with that spiked in blank
equine plasma. Product ion intensity ratio of dexamethasone in the test sample (upper panel) compared with calibrator (lower panel, left) and
with its isomer, betamethasone (lower panel, right) spiked in blank plasma, extracted and analyzed to ensure that the 3 criteria (similarity in
product ion intensity ratio, similarity in 3 ion transitions and in tR) established for confirmation of the presence of dexamethasone in the test
sample were satisfied. The difference in ion intensity ratio between the sample and the calibrator was < 20%.
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plasma sample as indicated in Figure 3A and Table 1. STR
profiles containing 21 equine STR markers were identical
in the samples (blood and hair) collected from the alleged
horse that had been sanctioned by the PA Racing Com-
mission and that of the post-race plasma sample, indicat-
ing that the post-race plasma was obtained from the
alleged horse. Due to insufficient quantity or quality of
sample, 18 out of 21 markers were detected in the post-
race urine sample and the 18 markers also matched those
of the subsequent samples collected from the alleged
horse (Figure 3B); this result further verified the origin of
all the samples analyzed. As expected, none of the human
DNA markers was detected in all the samples analyzed, in-
dicating that none of the equine samples analyzed was
contaminated by human DNA (data not shown).
In the present study, three STRs (HMS2, UM015 and
HMS1) were not detected in the test urine, indicating
typing deficiency of these STRs as well as limitation ofthe urine sample. It is not surprising that it is difficult to
show a complete STR profile in urine sample due to the na-
ture of the sample and especially after a substantial period
of storage (Chen et al., 2009). In an independent study con-
ducted, two random horses showed different STR profiles
and the profile of human hair did not show presence of the
horse STR fragments (data not shown). Again, these results
indicated that the findings for the alleged horse were cor-
roborated and that the STR genotyping method used is
valid for individual sample discrimination.
Plus A products of the amplified STRs were sequenced
using GenomeLab™ Dye Terminator Cycle Sequencing
Quick Start Kit (Beckman Coulter, Brea, CA, USA) (Chen
et al., 2010a). A single PCR product of plus A signal was
isolated from 6% polyacrylamide gel prior to sequencing.
Plus A peak was present in three loci including ASB9,
HMS7 and COR045. These plus A peaks were considered
artificial peaks that are frequently identified as an STR









































































































































































































Figure 3 Electropherograms of STR profiles from test plasma and test urine. 24-plex STR profiling was conducted according to the method
described previously (Chen et al., 2010a) and in the Case description. (A) 21 equine STR loci were detected in the test plasma. (B) 18 equine STR
loci were detected in the test urine.
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http://www.springerplus.com/content/3/1/943′ end of the fragment. The peak was one nucleotide lon-
ger than the real allelic peak and was not considered an al-
lele. For instance, two plus A peaks were detected at locus
COR045 in post-race samples and in those collected from
the alleged horse. In the blood sample collected from thesuspect horse, 218.93 and 229.39 were considered plus A
peaks (Figure 4A, arrows). In the post-race plasma, 218.85
and 229.31 were also considered plus A peaks (Figure 4B,
arrows). These two samples showed an identical peak pat-
tern at locus COR045 although plus A peak was presented
Table 1 Comparison of genotypes between suspect and test samples
VHL20 UMNe156 HTG4 AHT4 HMS6 HMS7 ASB9 ASB2 COR045 UMNe222 HMS3
Test plasma 18/18 21/21 19/20 33/33 19/20 20/22 14/21 22/22 15/21 10/16 25/25
Test urine 18/18 21/21 19/20 33/33 19/20 20/22 14/21 22/22 15/21 10/16 25/25
Suspect blood 18/18 21/21 19/20 33/33 19/20 20/22 14/21 22/22 15/21 10/16 25/25
Suspect hair 18/18 21/21 19/20 33/33 19/20 20/22 14/21 22/22 15/21 10/16 25/25
LEX074 COR008 HMS2 UM015 COR018 UMNe116 UMNe479 HMS1 UMNe191 LEX073
Test plasma 22/23 21/24 18/22 13/19 10.1/17 18/23 24/24 19/19 15/17 34/34
Test urine 22/23 21/24 ND ND 10.1/17 18/23 24/24 ND 15/17 34/34
Suspect blood 22/23 21/24 18/22 13/19 10.1/17 18/23 24/24 19/19 15/17 34/34
Suspect hair 22/23 21/24 18/22 13/19 10.1/17 18/23 24/24 19/19 15/17 34/34
ND: not detected.
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ASB9 and HMS7 (data not shown). The non-template
adenosine was confirmed by sequencing (GenBank acces-
sion #KJ021053, KJ021054, KJ021055, KJ021056, KJ021057

















































Figure 4 Electropherograms of allelic, plus A and stutter peaks at loc
COR045. The size of all peaks was labeled with the length of the amplified
Beckman Coulter). (A) COR045 profile for the suspect horse. (B) COR045 prfragment. Plus A peaks were smaller than their counterpart,
allelic peaks (56–79%).
Stutter activity was observed in most STR loci and peak
area ratios were 0.2-0.4, and were in agreement with those


















us COR045. Alleic, plus A and stutter peaks were detected at locus
DNA fragment as determined by Fragment Analysis software (v. 3.2.42;
ofile for the post-race plasma.
Table 2 Allele frequency for alleles detected in the
suspect Standardbred pacer horse and post-race samples
(n = 171)
STR Allele Frequency Allele Frequency
VHL20* 18 0.377 NA NA
UMNe156 21 0.544 NA NA
HTG4 19 0.108 20 0.099
AHT4* 33 0.474 NA NA
HMS6* 19 0.447 20 0.307
HMS7* 20 0.377 22 0.518
ASB9 14 0. 01 21 0.011
ASB2* 22 0.205 NA NA
COR045 15 0.01 21 0.146
UMNe222 10 0.175 16 0.693
HMS3* 25 0.272 NA NA
LEX074 22 0.240 23 0.301
COR008 21 0.129 24 0.477
HMS2* 18 0.386 22 0.082
UM015* 13 0.123 19 0.006
COR018* 10.1 0.064 17 0.594
UMNe116* 18 0.211 23 0.155
UMNe479* 24 0.711 NA NA
HMS1 19 0.345 NA NA
UMNe191* 15 0.020 17 0.243
LEX073* 34 0.249 NA NA
*Allele frequency was based on a database for Standardbred horses (n = 171)
(Chen et al. 2010a) and random match probability was estimated over 13
independent loci.
NA = not applicable.
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the suspect horse and the post-race plasma samples showed
an identical stutter pattern including stutter peaks of ap-
proximately 216 bp and 226 bp (Figure 4 double arrows).
The presence of the stutter activity did not influence inter-
pretation of the STR results since it was common and the
stutter peaks were identical in the two samples.
Using allele frequency as previously defined, random
match probability (RMP) was calculated as a product of
genotype frequency for identical alleles between samples
using 13 independent loci (Chen et al., 2010a, 2010b; Fung
et al., 2006). The computed probability is a measure of
matching probability between two random samples, and
thus, the smaller RMP indicates higher probability of a
match. RMP reflects the probability of a random animal as
a true donor and was calculated as the probability of
accepting a random horse being a culprit subject. RMP in
the present case study was 1.5 × 10-15 for the samples from
the alleged horse and 1.6 × 10-11 for the urine sample vs
samples from the alleged horse. Taken together, this result
indicated that the probability of drawing a false conclusion
regarding this case was nearly zero. Alleles detected in the
alleged and post-race samples were also detected in a pre-
vious study (Chen et al., 2010a). However, allele 14 at
locus ASB9 and allele 15 at locus COR045 were not previ-
ously reported (Table 2) although they were detected in
other case studies (not published). In the previous study,
the use of 13 independent loci to calculate RMP was vali-
dated. Those loci were located at different chromosome
and showed no linkage disequilibrium. The remaining eight
loci were not used in the estimation of the RMP because
of synteny. Among 21 loci, UMNe156, ASB2, UMNe222,
HMS1 are syntenic (chromosome 15); HTG4, COR008 and
HMS3 are syntenic (chromosome 9); AHT4 and LEX074
are syntenic (chromosome 24); ASB9, COR045 and HMS2
are syntenic (chromosome 10).
Discussion and evaluation
The presence of dexamethasone in the post-race plasma
sample from the alleged horse was detected, confirmed,
quantified and reported to the PA Racing Commission.
When the trainer was informed of the violation, he/she
immediately claimed that the sample could not have been
collected from his/her horse because he/she did not ad-
minister the drug to the horse and did not authorize any-
one to do so. In order for the Commission to resolve the
controversy, DNA test on the samples was ordered. Re-
sults obtained indicated that all the samples tested were
obtained from the same horse.
Dinucleotide-based STR profiling for individual discrim-
ination has been successfully employed in the horse (Chen
et al., 2010a; van de Goor et al., 2010). However, precision
in calling of alleles using dinucleotide STR loci in forensic
science presents a serious limitation. In human forensics,dinucleotide STR loci are no longer used because of the
frequent occurrence of stuttering and the difficulties with
precision in calling the true alleles, especially when the al-
lele span difference is one repeat unit. Similar to our sys-
tem, a previous proposal for standardization in forensic
equine DNA typing used 17 equine-specific STR loci, but
only 13 independent loci can be used for calculation of
RMP (van de Goor et al., 2010). However, a comprehen-
sive study showing a match of post-race samples with that
in which detection, quantification and confirmation of a
banned substance in a post-race equine plasma sample
had not previously been reported (Tobe et al., 2006). The
result obtained from the novel 24-plex STR genotyping
system unambiguously demonstrated that the post-race
equine plasma sample that tested positive for the presence
of dexamethsaone was collected from the same horse
(Table 1).
Plus A peak is a non-specific artifact during PCR
amplification of the STR markers and was common
(Brownstein et al., 1996; Clark, 1988) but had not been
reported in the equine (Bowling et al., 1997; van de Goor
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of promoting non-template addition of adenosine to the
3′ end of PCR–amplified products (Brownstein et al.,
1996). In comparison with stutter peaks (Chen et al.,
2010a: Walsh et al., 1996; Gill et al., 1997), plus A sig-
nals were easily detected by Fragment Analysis Software
(v. 3.2.42) incorporated in the Genetic Analysis System
(Beckman Coulter) and could be easily excluded during
data processing and genotype determination (Chen et al.,
2010a). Although dinucleotide STR loci are still being used
in equine STR profiling, exploring other means such as
equine-specific tetranucleotide STR loci, single nucleotide
polymorphism or analysis of mitochondrial DNA may be
an alternative or a better approach for interpreting and val-
idating genotyping result (Walsh et al., 1996; Breen et al.,
1994; Kakoi et al., 2013; Xu et al., 2011; Allen et al., 1998).
Following storage, the integrity of DNA in urine
sample was shown to decline thus, reducing the
chances of detecting alleles (Chen et al., 2009) but after
a month of storage at 4°C, most STRs were still de-
tected in the samples in the present study. It is evident
that the 24-plex STR typing system is capable of re-
vealing a complete STR profile with 21 markers from
30-day old refrigerated plasma sample although it had
been reported that long-term storage could decrease
the quality and quantity of DNA sample (Chen et al.,
2009). Identity of the post-race and alleged samples in
this study was confirmed by an independent laboratory
in California that analyzed the “B” samples using thir-
teen DNA markers (personal communication with the
PA Racing Commission). Like other genotyping systems
(Kakoi et al., 2013; van de Goor et al., 2010), the present
system is not perfect but it demonstrates a remarkable
success on a number of cases including dry blood stains
retained in a suspect syringe (Chen et al., 2010b) and is
accredited under ISO 17025 Guidelines as a standard
DNA test procedure. This is an intriguing study with re-
sults showing that on race day, an unauthorized drug, dex-
amethsaone, was detected in a post-race plasma sample
and that the origin of the sample was correctly identified.
Sample identification by DNA provided corroborated evi-
dence that the samples analyzed were obtained from the
same horse.Conclusion
The post-race plasma sample contained dexamethasone
as confirmed by LC/MS/MS and STR profile of the sam-
ple matched that of the suspect horse.
Abbreviations
DNA: Deoxyribonucleic acid; ESI: Electrospray ionization; IS: Internal standard;
LC-MS/MS: Liquid chromatography tandem mass spectrometry;
PCR: Polymerase chain reaction; RMP: Random match probability;
SRM: Selected reaction monitoring; STR: Short tandem repeat.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
J-WC carried out the genotyping studies and drafted the manuscript. CEU and
LRS supervised the study and revised the manuscript. YY carried out the LC-MS
study and analysis and obtained the mass spectral data. ZJ participated in the
genotyping study. XL and YL participated in the LC-MS study. FG participated in
analysis and interpretation of the mass spectral data. All authors read and
approved the manuscript.Acknowledgements
This study was funded by the PA Racing Commissions (Horse and Harness).
Financial contribution was made by the PA Harness Horseman Association at
Pocono and Chester Downs, Meadows Standardbred Owners Association,
Horsemen Benevolent and Protective Association at Penn National and
Presque Isle Downs to whom the authors are most grateful.
Received: 4 December 2013 Accepted: 14 January 2014
Published: 17 February 2014References
Allen M, Engström AS, Meyers S, Handt O, Saldeen T, von Haeseler A, Pääbo S,
Gyllensten U (1998) Mitochondrial DNA sequencing of shed hairs and saliva
on robbery caps: sensitivity and matching probabilities. J Forensic Sci
43:453–464
Bowling AT, Eggleston-Stott ML, Byrns G, Clark RS, Dileanis S, Wictum E (1997)
Validation of microsatellite markers for routine horse parentage testing.
Anim Genet 28(4):247–252
Breen M, Downs P, Irvin Z, Bell K (1994) An equine tetranucleotide repeat:
microsatellite MPZ001. Anim Genet 25(2):123
Brownstein MJ, Carpten JD, Smith JR (1996) Modulation of non-templated
nucleotide addition by Taq DNA polymerase: primer modifications that
facilitate genotyping. Biotechniques 20(6):1004–1010
Budowle B, Garofano P, Hellman A, Ketchum M, Kanthaswamy S, Parson W,
Haering WV, Fain S, Broad T (2005) Recommendations for animal DNA
forensic and identity testing. Int J Legal Med 119(5):295–302
Chen JW, Uboh CE, Soma LR, Li X, Guan F, You Y (2009) Microsatellite loci in
urine supernatant and stored samples from racehorses. Am J Vet Res 70
(5):648–657
Chen JW, Uboh CE, Soma LR, Li X, Guan F, You Y, Liu Y (2010a) Identification of
racehorse and sample contamination by novel 24-plex STR system.
Forensic Sci Int Genet 4(3):158–167
Chen JW, Uboh CE, Soma LR, Li X, Guan F, You Y, Liu Y (2010b) Determining the
source of equine bloodstains by dinucleotide repeats. J Forensic Sci 55
(6):1610–1614
Clark JM (1988) Novel non-templated nucleotide addition reactions catalyzed
by procaryotic and eucaryotic DNA polymerases. Nucleic Acids Res 16
(20):9677–9686
Fung WK, Hu YQ, Chung YK (2006) On statistical analysis of forensic DNA: theory,
methods and computer programs. Forensic Sci Int 162(1–3):17–23
Gill P, Sparkes R, Kimpton C (1997) Development of guidelines to designate
alleles using an STR multiplex system. Forensic Sci Int 89(3):185–197
Kakoi H, Kijima-Suda I, Gawahara H, Kinoshita K, Tozaki T, Hirota K,
Yoshizawa M (2013) Individual identification of racehorses from urine
samples using a 26-plex single-nucleotide polymorphism assay. J Forensic
Sci 58(1):21–28
Luo Y, Uboh CE, Soma LR, Guan F, Rudy JA, Tsang DS (2005) Resolution,
quantification and confirmation of betamethasone and dexamethasone
in equine plasma by liquid chromatography/tandem mass spectrometry.
Rapid Commun Mass Spectrom 19(6):825–832
Tobe SS, Reid SJ, Linacre AM (2006) Successful DNA typing of a drug positive
urine sample from a race horse. Forensic Sci Int 173:85–86
Van de Goor LH, Panneman H, van Haeringer WA (2010) A proposal for
standardization in forensic equine DNA typing: allele nomenclature for 17
equine-specific STR loci. Anim Genet 41(2):122–127
Van de Goor LH, van Haeringer WA, Lenstra JA (2011) Population studies of 17
equine STR for forensic and phylogenetic analysis. Anim Genet
42(6):627–633
Chen et al. SpringerPlus 2014, 3:94 Page 9 of 9
http://www.springerplus.com/content/3/1/94Walsh PS, Fildes NJ, Reynolds R (1996) Sequence analysis and characterization of
stutter products at the tetranucleotide repeat locus vWA. Nucleic Acids Res
24(14):2807–2812
Xu H, Han W, Zhao C, Manglai D (2011) A suspect horse excluded by analysis of
species- and male-specific DNA and mtDNA. Forensic Sci Int 207:e66–e68
You Y, Uboh CE, Soma LR, Guan F, Li X, Rudy JA, Liu Y, Chen J-W (2009)
Ultra-performance liquid chromatography/tandem mass spectrometry in
high-throughput detection, quantification and confirmation of anabolic
steroids in equine plasma. Rapid Commun Mass Spectrom 23(13):2035–2044
doi:10.1186/2193-1801-3-94
Cite this article as: Chen et al.: Identification of sample donor by 24-plex
short tandem repeat in a post-race equine plasma
containing dexamethasone. SpringerPlus 2014 3:94.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
